ArticlePakistan journal of medical sciences2026
FPN1-8C>G Polymorphism as a potential genetic modifier of iron overload in transfusion-dependent β-Thalassemia major patients receiving HbF augmentation therapy.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the association of the FPN1-8C>G polymorphism with iron overload and iron-regulatory biomarkers in transfusion-dependent β-thalassemia major patients receiving fetal hemoglobin (HbF) augmentation therapy. Methodology: This cross-sectional study was conducted from January 2024 to May 2025 at Fatima Hospital, Baqai Medical University, and Muhammadi Thalassemia Centre, Karachi, Pakistan. A total of 120 transfusion-dependent β-thalassemia major patients receiving hydroxyurea-based HbF augmentation therapy for at least six months were recruited through consecutive sampling. Conventional iron indices and serum hepcidin, erythroferrone (ERFE), growth differentiation factor-15 (GDF-15), and soluble transferrin receptor (sTfR) were measured. PCR-RFLP was performed for FPN1-8C>G genotyping, with Sanger sequencing confirmation. Results: The FPN1-8C>G variant was present in 39 (32.5%) patients. Iron overload was significantly associated with genotype ( Conclusions: FPN1-8C>G was significantly associated with greater iron burden and altered iron-regulatory biomarkers. It may represent a potential genetic marker of susceptibility to iron overload in transfusion-dependent β-thalassemia major; however, prospective validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.